UMN Pharma Inc. signed a license agreement with Protein Sciences Corporation in the US
This agreement allows UMN to use the exclusive rights of the development, manufacturing and sales of new recombinant influenza vaccines in Japan.

News release PDF file.  (50K)

In order to view this file, you will need to have the following plug-in installed.